Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA
Early initiation of TNF inhibitors among children with non-sJIA led to significant and sustained improvements in disease activity.
Researchers found that early initiation of tumor necrosis factor (TNF) inhibitor therapy among children diagnosed with nonsystemic juvenile idiopathic arthritis (non-sJIA) when aged 2 years or less leads to significant and sustained improvements in disease activity.
According to study results presented at the American College of Rheumatology (ACR) Convergence 2025, outcomes were comparable to patients who received treatment later in life and those not exposed to TNF inhibitors.
Using data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from 2015 to 2023, researchers aimed to describe the demographic and disease characteristics of children diagnosed with non-sJIA when aged from 0 to 23 months.
Author's summary: Early TNF inhibitor use improves non-sJIA outcomes.
More News
- Staffordshire Leader Reacts to "Squandered" Billions of Taxpayers' Money on Asylum Hotels - Staffordshire County Council Newsroom
- BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia
- Budget jitters see construction forecasts plummet
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- ICYMI: AAO 2025 showcases new technologies and continued research | Ophthalmology Times - Clinical Insights for Eye Specialists
- Key Asks from Government – As Staffordshire Finalises LGR Submission - Staffordshire County Council Newsroom
- Star Trek: Zachary Quinto Reprises Spock Role in Unexpected Way
- Biopic reintroduces female revolutionary hero - BusinessWorld Online
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow